Zealand Pharma AS (LTS:0NZU) EV-to-EBIT : -43.02 (As of Jan. 18, 2025)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zealand Pharma AS's Enterprise Value is kr42,323.93 Mil. Zealand Pharma AS's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was kr-983.84 Mil. Therefore, Zealand Pharma AS's EV-to-EBIT for today is -43.02.

The historical rank and industry rank for Zealand Pharma AS's EV-to-EBIT or its related term are showing as below:

LTS:0NZU' s EV-to-EBIT Range Over the Past 10 Years
Min: -89.64 Med: -12.68 Max: 8.02
Current: -43.02

During the past 13 years, the highest EV-to-EBIT of Zealand Pharma AS was 8.02. The lowest was -89.64. And the median was -12.68.

LTS:0NZU's EV-to-EBIT is ranked worse than
100% of 432 companies
in the Biotechnology industry
Industry Median: 9.535 vs LTS:0NZU: -43.02

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Zealand Pharma AS's Enterprise Value for the quarter that ended in Sep. 2024 was kr49,759.48 Mil. Zealand Pharma AS's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was kr-983.84 Mil. Zealand Pharma AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -1.98%.

Zealand Pharma AS EV-to-EBIT Historical Data

The historical data trend for Zealand Pharma AS's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS EV-to-EBIT Chart

Zealand Pharma AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-12.62

-11.41

-7.46

-10.52

-29.64

Zealand Pharma AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-EBIT	Get a 7-Day Free Trial															-27.54	-29.64	-68.57	-84.43	-50.16

Competitive Comparison of Zealand Pharma AS's EV-to-EBIT

For the Biotechnology subindustry, Zealand Pharma AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's EV-to-EBIT falls into.

Zealand Pharma AS EV-to-EBIT Calculation

Zealand Pharma AS's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	42323.925	/	-983.843
	=	-43.02

Zealand Pharma AS's current Enterprise Value is kr42,323.93 Mil.
Zealand Pharma AS's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-983.84 Mil.

Zealand Pharma AS (LTS:0NZU) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Zealand Pharma AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 )	=	EBIT	/	Enterprise Value (Q: Sep. 2024 )
	=	-983.843	/	49759.484375
	=	-1.98 %

Zealand Pharma AS's Enterprise Value for the quarter that ended in Sep. 2024 was kr49,759.48 Mil.
Zealand Pharma AS's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-983.84 Mil.

Zealand Pharma AS EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (LTS:0NZU) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines